Opexa to Present at Neurology Meeting

THE WOODLANDS, Texas -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), has announced that Edward Fox, MD, PhD, director of the Multiple Sclerosis Clinic of Central Texas and the principal investigator and co-author of the TERMS (Tovaxin® for Early Relapsing Multiple Sclerosis) clinical study will present data from the Phase IIb TERMS clinical trial at the upcoming American Academy of Neurology (AAN) 61st Annual Meeting to be held in Seattle, WA.

Dr. Fox will present the data during a poster session on Wednesday, April 29, 2009 from 4-7 p.m. at Poster Session VI, located at P06.132 in the poster hall under the following title: TERMS Trial T-Cell Vaccination Secondary Analysis of Clinical and Immunologic Outcomes in Relapsing Remitting Multiple Sclerosis Patients.

Source: Opexa Therapeutics, Inc.